---
bibliography: 'morinlab.bib'
csl: 'NLM.csl'
link-citations: true
---
[[_TOC_]]

## Overview
MGA acts as a transcriptional repressor and interacts with MYC, a well-known oncogene. Mutations in MGA have been described in DLBCL.<sup>1</sup> One study suggested MGA mutations were more common in DLBCLs in patients of African ancestry.<sup>2</sup> The mutation pattern in MGA is consistent with a role as a tumour suppressor gene. 


## Relevance tier by entity

|Entity|Tier|Description               |
|:------:|:----:|--------------------------|
|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
|![DLBCL](images/icons/DLBCL_tier1.png) |1   |high-confidence DLBCL gene[@reddyGeneticFunctionalDrivers2017]|

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

[[include:DLBCL_MGA.md]]

## Mutation pattern and selective pressure estimates

[[include:dnds_MGA.md]]

[[include:browser_MGA.md]]

## Expression
![](images/gene_expression/MGA_by_pathology.svg)

[[include:mermaid_MGA.md]]

## References


<!-- ORIGIN: zhangGeneticHeterogeneityDiffuse2013 -->
<!-- MZL: jalladesExomeSequencingIdentifies2017 -->
<!-- DLBCL: zhangGeneticHeterogeneityDiffuse2013 -->
